Core Viewpoint - Green Bamboo Bio-B (02480) reported a significant decline in other income and a narrowed net loss for the six months ending June 30, 2025, while achieving key milestones for its core product LZ901 [1] Financial Performance - Other income amounted to 4.85 million RMB, representing a year-on-year decrease of 50.2% [1] - The net loss was 77.57 million RMB, which is a 29.4% reduction compared to the previous year [1] - Basic loss per share was 0.39 RMB [1] Product Development - In January 2025, the company submitted a Biologics License Application (BLA) for LZ901 to the National Medical Products Administration, which was accepted in February 2025 [1] - Following the acceptance of the BLA, the National Medical Products Administration will conduct further evaluations, including technical reviews and inspections [1] - The company successfully completed a head-to-head comparative study for LZ901, showing superior cellular immune response and better safety compared to the HZ/su vaccine (Shingrix) in adults aged 50 and above [1] - The board believes these positive results lay a solid foundation for the future commercialization of LZ901 [1]